Comparative Pharmacology
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus SUFLAVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMOTIDINE CALCIUM CARBONATE AND MAGNESIUM HYDROXIDE versus SUFLAVE.
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE vs SUFLAVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine is a competitive histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking H2 receptors on parietal cells. Calcium carbonate and magnesium hydroxide act as antacids, neutralizing gastric acid via chemical neutralization.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
1 tablet (famotidine 10 mg, calcium carbonate 800 mg, magnesium hydroxide 165 mg) orally once or twice daily as needed for heartburn; maximum 2 tablets in 24 hours.
250 mg intravenously every 12 hours.
None Documented
None Documented
Famotidine: 2.5-3.5 hours (prolonged in renal impairment, up to 20 hours when CrCl <10 mL/min).
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Famotidine: renal (65-70% unchanged), biliary/fecal (30-35%). Calcium carbonate: feces (unabsorbed calcium), urine (absorbed). Magnesium hydroxide: feces (unabsorbed magnesium), urine (absorbed).
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Category A/B
Category C
Antacid / Laxative
Laxative